Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

http://undervaluedreport.com/2013/04/22/amarantus-bioscience-holdings-inc-otcqbambs/

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson’s, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company’s new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.”

IOW, more than one year ago, when folks were saying that we would get MANF and PD data in 2013 and revenue soon because of orphan status, Joe Rubenfeld himself said that the MANF for PD was NOT the priority, as GC finally admitted at THIS One Med Forum conference.

( I remembered that Joe R had said this. I was able to go back and find it in a related article. This year I am much more organized, as I have a digital paperport file for AMBS. It is getting pretty large. )

You should not be surprised about the change in priority noted by GC at 12:30 of this conference.

http://www.media-server.com/m/p/i98tbt59